JP4353684B2 - １−［１−（ヘテロ）アリール−１−ペルヒドロキシアルキルメチル］−ピペラジン化合物、その製法、薬学的組成物を製造するための該化合物の使用、および該化合物を製造するための出発化合物 - Google Patents

１−［１−（ヘテロ）アリール−１−ペルヒドロキシアルキルメチル］−ピペラジン化合物、その製法、薬学的組成物を製造するための該化合物の使用、および該化合物を製造するための出発化合物 Download PDF

Info

Publication number
JP4353684B2
JP4353684B2 JP2002265969A JP2002265969A JP4353684B2 JP 4353684 B2 JP4353684 B2 JP 4353684B2 JP 2002265969 A JP2002265969 A JP 2002265969A JP 2002265969 A JP2002265969 A JP 2002265969A JP 4353684 B2 JP4353684 B2 JP 4353684B2
Authority
JP
Japan
Prior art keywords
substituted
butyl
compound
dichlorophenyl
piperazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002265969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003113160A (ja
Inventor
ジャスラン ダニエル
プロイショフ ウルフ
アンテル ヨヘン
ダーヴィット ザミュエル
ザン ホルガー
ブリュックナー ラインハルト
ライヒェ ダーニア
エックフート クリスティアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Publication of JP2003113160A publication Critical patent/JP2003113160A/ja
Application granted granted Critical
Publication of JP4353684B2 publication Critical patent/JP4353684B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
JP2002265969A 2001-09-13 2002-09-11 １−［１−（ヘテロ）アリール−１−ペルヒドロキシアルキルメチル］−ピペラジン化合物、その製法、薬学的組成物を製造するための該化合物の使用、および該化合物を製造するための出発化合物 Expired - Fee Related JP4353684B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10145044.3 2001-09-13
DE10145044A DE10145044A1 (de) 2001-09-13 2001-09-13 Neue 1-[1-(Hetero)aryl-1-perhydroxyalkylmethyl]-Piperazinverbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
JP2003113160A JP2003113160A (ja) 2003-04-18
JP4353684B2 true JP4353684B2 (ja) 2009-10-28

Family

ID=7698848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002265969A Expired - Fee Related JP4353684B2 (ja) 2001-09-13 2002-09-11 １−［１−（ヘテロ）アリール−１−ペルヒドロキシアルキルメチル］−ピペラジン化合物、その製法、薬学的組成物を製造するための該化合物の使用、および該化合物を製造するための出発化合物

Country Status (26)

Country Link
US (1) US6770649B2 (https=)
EP (1) EP1293506B1 (https=)
JP (1) JP4353684B2 (https=)
KR (1) KR100909746B1 (https=)
CN (1) CN1232513C (https=)
AR (1) AR036487A1 (https=)
AT (1) ATE305464T1 (https=)
AU (1) AU2002301141B2 (https=)
BR (1) BR0203716A (https=)
CA (1) CA2403139C (https=)
DE (2) DE10145044A1 (https=)
DK (1) DK1293506T3 (https=)
DZ (1) DZ3292A1 (https=)
ES (1) ES2250561T3 (https=)
HU (1) HU227612B1 (https=)
IL (1) IL151497A (https=)
MX (1) MXPA02008789A (https=)
NO (1) NO324867B1 (https=)
NZ (1) NZ521154A (https=)
PL (1) PL356018A1 (https=)
PT (1) PT1293506E (https=)
RU (1) RU2301807C2 (https=)
SI (1) SI1293506T1 (https=)
TW (1) TWI254046B (https=)
UA (1) UA75590C2 (https=)
ZA (1) ZA200206731B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870396B1 (en) * 2005-03-31 2012-10-31 Nippon Zoki Pharmaceutical Co. Ltd. Benzyloxypropylamine derivative
US7592344B2 (en) 2005-11-30 2009-09-22 Solvay Pharmaceuticals Gmbh NK1 and NK2-antagonists and compositions and methods of using the same
JP2009517443A (ja) * 2005-11-30 2009-04-30 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のｎｋ１およびｎｋ２拮抗薬
CN103387549A (zh) * 2012-05-10 2013-11-13 广州医学院 三个苯并三氮唑类芳基哌嗪化合物的消旋体和光学异构体及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1575904A (en) * 1976-04-23 1980-10-01 Lilly Industries Ltd Phenyl piperazines
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
EP0709375B1 (en) * 1994-10-25 2005-05-18 AstraZeneca AB Therapeutic heterocycles
DE60114597T2 (de) * 2000-04-06 2006-07-20 Astrazeneca Ab Naphthamid-neurokinin antagonisten zur verwendung als medikamente

Also Published As

Publication number Publication date
DE50204379D1 (de) 2006-02-09
RU2301807C2 (ru) 2007-06-27
TWI254046B (en) 2006-05-01
MXPA02008789A (es) 2003-03-18
HUP0202967A3 (en) 2004-04-28
RU2002124199A (ru) 2004-03-20
ATE305464T1 (de) 2005-10-15
SI1293506T1 (sl) 2005-12-31
HK1053648A1 (en) 2003-10-31
KR20030023500A (ko) 2003-03-19
IL151497A (en) 2011-10-31
DK1293506T3 (da) 2005-10-17
HU227612B1 (en) 2011-09-28
PT1293506E (pt) 2005-11-30
DE10145044A1 (de) 2003-04-03
ES2250561T3 (es) 2006-04-16
AR036487A1 (es) 2004-09-15
CA2403139C (en) 2011-02-22
NO324867B1 (no) 2007-12-17
DZ3292A1 (fr) 2005-05-14
US6770649B2 (en) 2004-08-03
ZA200206731B (en) 2003-04-11
HUP0202967A2 (hu) 2003-06-28
UA75590C2 (en) 2006-05-15
NO20024351D0 (no) 2002-09-12
CA2403139A1 (en) 2003-03-13
CN1406937A (zh) 2003-04-02
NZ521154A (en) 2004-02-27
US20030125557A1 (en) 2003-07-03
JP2003113160A (ja) 2003-04-18
HU0202967D0 (https=) 2002-10-28
CN1232513C (zh) 2005-12-21
IL151497A0 (en) 2003-04-10
BR0203716A (pt) 2003-06-03
PL356018A1 (en) 2003-03-24
AU2002301141B2 (en) 2008-11-06
KR100909746B1 (ko) 2009-07-29
EP1293506A1 (de) 2003-03-19
NO20024351L (no) 2003-03-14
EP1293506B1 (de) 2005-09-28

Similar Documents

Publication Publication Date Title
JP2001525804A (ja) プロテアーゼ阻害剤
KR100196985B1 (ko) 피페리딘 유도체
JP4353684B2 (ja) １−［１−（ヘテロ）アリール−１−ペルヒドロキシアルキルメチル］−ピペラジン化合物、その製法、薬学的組成物を製造するための該化合物の使用、および該化合物を製造するための出発化合物
CZ290442B6 (cs) (R)-5-Brom-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridinkarboxamid, způsob jeho přípravy a farmaceutický prostředek, který jej obsahuje
JPH05262766A (ja) ピペリジルメチル−置換クロマン誘導体
JPH0358987A (ja) 新規化合物、その製法及びそれを含む医薬組成物
JP4564846B2 (ja) アロイル−ピペリジン誘導体
EP1954678B1 (en) Novel nk1 and nk2 antagonists
US7592344B2 (en) NK1 and NK2-antagonists and compositions and methods of using the same
HK1053648B (en) Novel 1-(1-(hetero)aryl-1-perhydroxyalkylmethyl)-piperazine compounds, process for their preparation and medicaments containing these compounds
LEVOIN et al. 19, United States i, Patent Application Publication to, Pub. No.: US 2013/0324506 A1
HK1121138B (en) Nk1 and nk2 antagonists
JPWO2004024143A1 (ja) 医薬組成物
JPH1171378A (ja) トリアゾロ−１，４−ジアゼピン系化合物
JPH04210970A (ja) ベンズアミド誘導体及びその中間体
HK1057864B (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
JP2010031063A (ja) 医薬組成物
JPH08506360A (ja) 新規置換化チオセミカルバゾン酸エステル

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090617

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090715

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090728

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120807

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees